Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
RANCHO CUCAMONGA, CA / / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits BAQSIMI®, including its potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact:
Bill PetersChief Financial Officer(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Why Palantir Technologies Hit a New All-Time High on Wednesday
One Wall Street analyst boosted Palantir's price target, despite maintaining a sell rating. The reasoning for the move was decidedly bullish. The key factor in the rating is Palantir's frothy valuation. 10 stocks we like better than Palantir Technologies › Palantir Technologies (NASDAQ: PLTR) stock continued its epic run on Wednesday, climbing as much as 5.4%. As of 3:37 p.m. ET, the stock was still up 3%. The artificial intelligence (AI) software and data mining specialist has climbed to new heights several times in recent weeks, with its stock notching a new all-time high on Wednesday. That puts the stock up more than 80% so far this year. The catalyst behind today's move was a reluctant nod from a Wall Street analyst. Mizuho analyst Matthew Broome kept an underperform (sell) rating on Palantir stock, but raised his price target for Palantir to $116, up from its previous level of $94. For those keeping score at home, that's roughly 12% below the stock's closing price on Tuesday, so the analyst is obviously playing catch-up. Broome cited Palantir's "strong recent execution and significant upward revisions" for his price target increase. The analyst also noted the company's "strong strategic positioning with large customers and potential for further accelerated growth in future years." So, if the analyst is so bullish on Palantir, why maintain the sell rating? In a word: valuation. Palantir stock is currently selling for 594 times earnings and 109 times sales. With multiples of that magnitude, it isn't for the faint of heart. Even factoring in the company's accelerating growth, it sports a price-to-earnings growth (PEG) ratio of 6, when any number higher than 1 is overvalued. Don't get me wrong: I'm a dyed-in-the-wool Palantir bull. However, valuation is a fickle mistress, and any failure by the company to execute -- real or perceived -- could bring the stock crashing down. In fact, I wouldn't be surprised to see Palantir stock get cut in half at some point over the next year -- before climbing to even greater heights. Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Danny Vena has positions in Palantir Technologies. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. Why Palantir Technologies Hit a New All-Time High on Wednesday was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
‘Global arms race with artificial intelligence': TN rep. supports xAI project moving forward
MEMPHIS, Tenn. — A state representative from Memphis says he supports Elon Musk's xAI, and says the company is planning up to eight more sites in the area. Republican state Rep. John Gillespie's comments came after state representatives had a press conference on Tuesday against the project moving forward. 'Why is economic development always at the cost of poor folk? Always at the cost of low wel people? We as a city have to have higher self-esteem, we as a city have to believe better about who we are,' said State Rep. Justin J. Pearson, (D-Memphis). Pearson and other democratic lawmakers met with Memphis Mayor Paul Young on Tuesday. Republican Rep. John Gillespie (R-Memphis) says he was there too, and he has a different take on xAI. Memphis mayor meets with state leaders over xAI concerns 'I'm extremely excited and the potential of all the other things that will follow,' said Gillespie. 'We're in a global arms race with artificial intelligence.' 'We're competing not with Silicon Valley, but we're actually competing with China and Russia, and North Korea. xAI and people at xAI have said that they plan on winning that arms race,' said Gillespie. In a statement, he talked about the large amount of tax dollars the company brings also saying, 'Hundreds of Memphians are currently working in construction as xAI plans to build on at least eight sites in Shelby County. ' Rep. Justin Pearson, NAACP aim to halt xAI project in Memphis 'Right now if you do look up, xAI has four sites right now that they have and they've publicly said more are to come. I don't know how many that number is, I hope it's more than eight but I suspect it will be more than eight as well,' said Gillespie. 'Well the data that I've seen and the health department has confirmed and the manufacturer of the turbines have also confirmed, they have technology on there that makes it no more than a dry cleaning or a gas station,' said Gillespie. Mayor Paul Young said there are plans to bring more community-based testing of the air quality in the area of xAI. 'My goal is to make sure our people are protected from a health perspective and that we use this project to boost our city economically,' said Mayor Young. Gillespie says he's all for the testing. It's unclear when that testing will be happening in southwest Memphis and the Boxtown community. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
